A Phase 4 interventional study of Roflumilast and intralesional steroid in Alopecia and Alopecia Areata, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 18 Weeks and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Cairo University · Phase 4, Interventional, and Treatment
Evaluation of the Efficacy and Safety of a drug called Oral Roflumilast versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata.
we are going to evaluate using oral immunomodulator called Roflumilast and compare its safety and efficacy to intralesional steroid injection in the treatment of Alopecia areata
609 studies on the registry are indexed under Alopecia; 131 are open to participants now.
This study's enrollment of 50 is above the median of 45 across 513 interventional studies indexed under Alopecia.
Browse Alopecia studies →Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
patients in arm A will receive daily oral Roflumilast (immunomodulator) 500 mcg for 16Consecutive weeks.
Drug: Roflumilast
ILCs group: 5 mg/mL every 4 weeks for 16 weeks
Drug: intralesional steroid
Phosphodiesterase-4 (PDE4) inhibitor assigned to arm A
intralesional injection of corticosteroid
To assess the degree of improvement in hair regrowth according to the change in SALT score from baseline to Week 16.
To assess the degree of improvement in hair regrowth according to the change in SALT score from baseline to Week 16.
Time frame: 4 months
Plan to share: Yes — age, sex
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University